- Home
- HAO
HAO
HAOXI HEALTH TECHNOLOGY LTD
as 04-01-2025 3:37pm EST
Stocks
| Founded: | 2018 | Country: | China |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | 2024 |
| Target Price: | N/A | AVG Volume (30 days): | 7.0M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.04 | EPS Growth: | 20.20 |
| 52 Week Low/High: | $0.09 - $10.60 | Next Earning Date: | 10-29-2024 |
| Revenue: | $48,519,836 | Revenue Growth: | 71.88% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest HAOXI HEALTH TECHNOLOGY LTD News
HAO Breaking Stock News: Dive into HAO Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Haoxi Health Technology Limited Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
GlobeNewswire
2 months ago
Haoxi Health Technology Limited Announces 1-for-25 Reverse Share Split
Simply Wall St.
2 months ago
Is Haoxi Health Technology Limited's (NASDAQ:HAO) 11% ROE Better Than Average?
GlobeNewswire
4 months ago
Haoxi Health Technology Limited Awarded a RMB30 Milllion Framework Contract to Provide Digital Advertising Services for Tengyuan Media Advertising Co., Ltd.
GlobeNewswire
5 months ago
Haoxi Health Technology Limited Receives Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
GlobeNewswire
5 months ago
Haoxi Health Technology Limited Reports Financial Results for Fiscal Year Ended June 30, 2024
TipRanks
6 months ago
Haoxi Health Technology sees FY24 revenue $48.52M vs. $28.23M last year
GlobeNewswire
6 months ago
Haoxi Health Technology Limited Announces Preliminary Unaudited FY24 Financial Results with projected 72% Revenue Growth
Compare HAO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HAO HAOXI HEALTH TECHNOLOGY LTD - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.